Placebo News and Research

RSS

Study shows how local anesthetics can improve motor skills of patients after stroke

Painkilling drugs that make many therapies possible are a blessing for patients. Thanks to modern anesthetics, not only can surgical operations be conducted without causing pain, they are also used for various diagnostic procedures. Anesthetics can be very useful in therapies for stroke patients, as psychologists and physicians of the Friedrich Schiller University Jena (Germany) and the University Hospital Jena are now able to prove.

6 Nov 2012

Alnylam third quarter 2012 revenues decrease to $16.8 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the third quarter 2012, and company highlights.

6 Nov 2012

Intravenous infusion of HDL cholesterol could reduce risk of subsequent heart attack

An intravenous infusion of good cholesterol could reduce the risk of a subsequent heart attack, researchers reported at the American Heart Association's Scientific Sessions 2012.

6 Nov 2012

No link between daily multivitamin use and reduction of major cardiovascular events in men

In a randomized study that included nearly 15,000 male physicians who were middle-aged or older, daily multivitamin use for more than 10 years of treatment and follow-up did not result in a reduction of major cardiovascular events, heart attack, stroke, or death from cardiovascular disease, according to a study appearing in November 7 issue of JAMA, a theme issue on cardiovascular disease.

5 Nov 2012

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has dosed the first subjects in a Phase 2, placebo-controlled, dose-finding study of its ARX-04 sufentanil NanoTab product candidate.

5 Nov 2012

Study highlights potential treatment that reduces kidney growth

Autosomal-dominant polycystic kidney disease (ADPKD) is one of the most common genetic disorders, affecting one in every 1,000 people and responsible for up to ten percent of patients on dialysis worldwide. The disease is characterized by the development of cysts that lead to progressive kidney failure and necessitate dialysis or a kidney transplant in most patients aged around fifty. Moreover, the persistent cyst growth causes high blood pressure and painful complications.

5 Nov 2012

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Amgen will present data from four Phase 2 trials of AMG 145, an investigational fully human monoclonal antibody directed against PCSK9, a protein that reduces the liver's ability to remove low density lipoprotein cholesterol, or "bad" cholesterol from the blood, at the upcoming American Heart Association Scientific Sessions 2012.

3 Nov 2012

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

A drug therapy shows promise for treating an inherited form of kidney disease called autosomal dominant polycystic kidney disease (ADPKD), Mayo Clinic researchers say.

3 Nov 2012

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

Aerie Pharmaceuticals, a biotechnology company focused on the discovery and development of novel treatments for glaucoma, today announced positive top-line results from its Phase 2a study evaluating AR-13324 for the treatment of glaucoma.

3 Nov 2012

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.

3 Nov 2012

$Denosumab gives FREEDOM to heal fractures$

Denosumab gives FREEDOM to heal fractures

Results from the FREEDOM trial indicate that fracture healing is not impaired in women with osteoporosis who use the antiresorptive therapy denosumab.

2 Nov 2012

TD-1211 may relieve opioid-induced constipation

TD-1211 – an inhibitor of the mµ-opioid receptor – alleviates chronic noncancer-related constipation in patients receiving opioid therapy, without affecting pain relief, show the results of a parallel-group study.

2 Nov 2012

CD22 protein could prove to be important new target for anti-cancer therapy

A team of UC Davis investigators has discovered a protein on the surface of lung cancer cells that could prove to be an important new target for anti-cancer therapy. A series of experiments in mice with lung cancer showed that specific targeting of the protein with monoclonal antibodies reduced the size of tumors, lowered the occurrence of metastases and substantially lengthened survival time.

2 Nov 2012

Soy products do not prevent onset of vasomotor symptoms in women

A team of investigators led by UC Davis found that eating soy products such as soy milk and tofu did not prevent the onset of hot flashes and night sweats as women entered menopause.

2 Nov 2012

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Inotek Pharmaceuticals Corp., a leader in the development of innovative drug candidates to address significant diseases of the eye, today announced that final data from a Phase 2 clinical trial of trabodenoson, also known as INO-8875, in patients with primary open-angle glaucoma or ocular hypertension will be presented at the Ophthalmology Innovation Summit on Thursday, November 8, 2012 at the Chicago Marriott Downtown Magnificent Mile in Chicago, IL.

2 Nov 2012

Genetic underpinning of placebo effect identified

US researchers have identified a gene that appears to be responsible for the placebo effect.

1 Nov 2012

Clinical hypnosis can effectively reduce hot flashes among postmenopausal women

Clinical hypnosis can effectively reduce hot flashes and associated symptoms among postmenopausal women, according to a new study conducted by researchers at Baylor University's Mind-Body Medicine Research Laboratory.

1 Nov 2012

Controlling depression can improve health status and social functioning in patients with heart failure

Controlling depression in patients with heart failure can improve health status, social functioning and quality of life, according to a new study by psychiatrists and cardiologists at the UC Davis and Duke University schools of medicine.

1 Nov 2012

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

EnVivo Pharmaceuticals, a company dedicated to developing a broad range of novel central nervous system (CNS) therapies, today presented pharmacokinetic and pharmacodynamic data along with the previously reported statistically significant clinical results from its Phase 2b clinical trial of EVP-6124, a novel alpha-7 agonist, in patients with Alzheimer's disease.

1 Nov 2012

AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy

Asahi Kasei Pharma America Corp. today announced the initiation of an 800-patient Phase 3 clinical trial for ART-123 (recombinant human thrombomodulin, marketed as Recomodulin in Japan) in severe sepsis patients with coagulopathy.

1 Nov 2012

Placebo News and Research

Study shows how local anesthetics can improve motor skills of patients after stroke

Alnylam third quarter 2012 revenues decrease to $16.8 million

Intravenous infusion of HDL cholesterol could reduce risk of subsequent heart attack

No link between daily multivitamin use and reduction of major cardiovascular events in men

AcelRx commences dosing in ARX-04 sufentanil NanoTab Phase 2 study for acute and breakthrough pain

Study highlights potential treatment that reduces kidney growth

Data from four Phase 2 trials of AMG 145 to be presented at AHA Scientific Sessions 2012

Tolvaptan shows promise in treating autosomal dominant polycystic kidney disease

Top-line results from Aerie Pharmaceuticals' AR-13324 Phase 2a study on glaucoma

FDA expands Janssen’s Xarelto use to reduce risk of DVT and PE

Denosumab gives FREEDOM to heal fractures

TD-1211 may relieve opioid-induced constipation

CD22 protein could prove to be important new target for anti-cancer therapy

Soy products do not prevent onset of vasomotor symptoms in women

Inotek announces final data from trabodenoson Phase 2 trial on PAOG or ocular hypertension

Genetic underpinning of placebo effect identified

Clinical hypnosis can effectively reduce hot flashes among postmenopausal women

Controlling depression can improve health status and social functioning in patients with heart failure

Additional data from EnVivo’s EVP-6124 Phase 2b trial on AD presented at CTAD meeting

AKP America commences ART-123 Phase 3 trial in severe sepsis patients with coagulopathy

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News